Based on the Allakos stock forecast from 3 analysts, the average analyst Allakos stock price target is USD 3.67 over the next 12 months. Allakos Inc’s average analyst rating is Hold. Stock Target Advisor’s own stock analysis of ALLK stock forecast is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Allakos stock price was USD 3.81. Allakos stock price has changed by -0.19% over the past week, +0.45% over the past month and -95.58% over the last year.
About Allakos Inc. (ALLK:NSD):
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
What we like:
There is nothing we particularly like about Allakos stock.
What we don’t like:
The total returns for ALLK stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
ALLK stock had negative total cash flow in the most recent four quarters.
Negative free cash flow:
ALLK stock had negative total free cash flow in the most recent four quarters.
Low Earnings Growth:
ALLK stock has shown below median earnings growth in the previous 5 years compared to its sector
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.